

Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO

Wednesday, May 16, 2018 - 01:00pm

Data span 13 therapies across 16 types of cancer aimed at transforming patient care

Pfizer Inc. today announced that new data from its diversified portfolio of marketed and investigational oncology medicines will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5, 2018. Data from programs in small molecules, immunotherapies, biomarker-driven medicines, as well as biosimilars, will be featured in more than 40 abstracts, including company-sponsored and collaborative research studies.

“The breadth and depth of our data at ASCO this year are indicative of our focus on understanding the full potential of our medicines, including IBRANCE® and XTANDI®, which are already making a difference in patient lives. We are also exploring new and exciting pathways designed to transform treatment outcomes,” said Charles Hugh-Jones, MD, FRCP, chief medical officer, Pfizer Oncology. “Our comprehensive research is resulting in near-term potential benefits for patients, as well as multiple new therapies that we hope to introduce this year.”

The research to be presented includes new insights on Pfizer’s late-phase investigational compounds dacomitinib, lorlatinib, talazoparib and glasdegib, as well as Pfizer’s marketed therapy XTANDI® (enzalutamide). These compounds represent the next five potential Pfizer Oncology advancements in lung, breast, hematologic and prostate cancers.

“At this year’s ASCO, we’re particularly excited to present overall survival data for dacomitinib that builds upon our precision medicine focus and legacy in lung cancer,” said Mace Rothenberg, MD, chief development officer, Oncology, Pfizer Global Product Development. “Further, we’ll be sharing new insights on our medicines across 16 disease areas and 13 mechanisms of action, including early-phase through post-approval analyses. Our extensive presence reinforces our commitment to speeding accessible breakthrough medicines to patients.”

Key Pfizer abstracts include:

The first presentation of final overall survival results from the pivotal ARCHER 1050 study of dacomitinib vs. gefitinib in locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutation

Phase 2 results from a clinical research collaboration evaluating IBRANCE® (palbociclib) in combination with cetuximab in platinum-resistant HPV unrelated recurrent/metastatic head and neck squamous cell carcinoma
An analysis of resistance to therapy based on genetic mutations from the pivotal PALOMA-3 trial of CDK 4/6 inhibitor IBRANCE in combination with fulvestrant in ER+/HER2- metastatic breast cancer

Longer-term efficacy and safety results from two registrational trials: the JAVELIN Merkel 200 study of PD-L1 inhibitor BAVENCIO® (avelumab) in a rare skin cancer, being developed in collaboration with Merck KGaA,

Darmstadt, Germany and the BFORE trial of BOSULIF® (bosutinib) vs. imatinib in patients with newly diagnosed chronic myeloid leukemia

A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer

Details for the Pfizer-sponsored oral presentations are below:

Title/Abstract Number	Date/Time (CDT)	Location
(Abstract 9008) Avelumab (anti-PD-L1) in Combination with Crizotinib or Lorlatinib in Patients with Previously Treated Advanced NSCLC: Phase 1b Results from JAVELIN Lung 101	Friday, June 1 4:30 PM – 6:00 PM	Hall D1
Shaw A (Abstract 7002) Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: 24-Month Follow-Up	Saturday, June 2 3:00 PM – 6:00 PM	E450
Cortes J (Abstract 1001) Genetic Landscape of Resistance to CDK4/6 Inhibition in Circulating Tumor DNA (ctDNA) Analysis of the PALOMA3 Trial of Palbociclib and Fulvestrant Versus Placebo and Fulvestrant	Sunday, June 3 8:00 AM – 11:00 AM	Hall D2
Turner N (Abstract 6008)	Sunday, June 3	E451

Multicenter Phase 2
Trial of Palbociclib, a
Selective Cyclin
Dependent Kinase
(CDK) 4/6 Inhibitor,
and Cetuximab in
Platinum-Resistant
HPV Unrelated (-)
Recurrent/Metastatic
Head and Neck
Squamous Cell
Carcinoma (RM
HNSCC)

8:00 AM – 11:00 AM

Adkins D

(Abstract 9507) Monday, June 4

Arie
Crown
Theater

Two-Year Efficacy
and Safety Update
from JAVELIN
Merkel 200 Part A: A
Registrational Study
of Avelumab in
Metastatic Merkel
Cell Carcinoma
Progressed on
Chemotherapy

8:00 AM – 11:00 AM

Nghiem P
(Abstract 109) Monday, June 4

Hall D1

A Comparative
Clinical Study of PF-
06439535, a
Candidate
Bevacizumab
Biosimilar, and
Reference
Bevacizumab, in
Patients with
Advanced Non-
Squamous Non-Small
Cell Lung Cancer

9:45 AM – 11:15 AM

Socinski M		
(Abstract 9004)	Monday, June 4	Hall B1
Dacomitinib (daco)		
Versus Gefitinib (gef)		
for First-Line		
Treatment of		
Advanced NSCLC	3:00 PM – 6:00 PM	
(ARCHER 1050):		
Final Overall		
Survival (OS)		
Analysis		

Please see a complete list of Pfizer-sponsored abstracts featuring data on our broad pipeline of biologics and small molecules at <https://www.pfizer.com/files/news/asco/Pfizer-Oncology-Data-Presentations-ASCO-2018.pdf>.

Learn more about how developing new medicines and supporting people with cancer is personal for Pfizer Oncology at http://www.pfizer.com/research/therapeutic_areas/oncology.

Dacomitinib, lorlatinib, talazoparib and glasdegib are investigational agents and have not been approved by any regulatory agencies.

Please see full Prescribing Information for BAVENCIO® (avelumab) at www.Bavencio.com.

Please see full Prescribing Information for BOSULIF® (bosutinib) at www.Bosulif.com.

Please see full Prescribing Information for IBRANCE® (palbociclib) at www.Ibrance.com.

Please see full Prescribing Information for XTANDI® (enzalutamide) at www.Xtandi.com.

About Pfizer Oncology

Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on people living with cancer. Our growing pipeline of biologics, small molecules, and immunotherapies is focused on identifying and translating the best scientific breakthroughs into clinical application for patients across a diverse array of solid tumors and hematologic cancers. Today, we have 10 approved oncology medicines and 14 assets currently in clinical development. By maximizing our internal scientific resources and collaborating with other companies, government and academic institutions, as well as patients and non-profit and professional organizations, we are bringing together the brightest and most enterprising minds to take on the toughest cancers. Together we can accelerate breakthrough treatments to patients around the world and work to redefine life with cancer.

Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to

Media Contact: Jessica Smith, 212-733-6213 Jessica.M.Smith@pfizer.com or Investor Contact: Ryan Crowe,
212-733-8160 Ryan.Crowe@pfizer.com